Nova Scotia introduces biosimilars switching program

Feb 4, 2022

Nova Scotia launched a biosimilars switching program.  The program applies to certain insulins and products used for arthritis, IBD and psoriasis and pharmacare beneficiaries will have 12 months to apply the switch to biosimilars.  Similar programs have already been introduced in British Columbia, Quebec, Alberta and New Brunswick.

Print Page Mail Article